Testing effectiveness (Phase 2)Study completedNCT06173037
What this trial is testing
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Who this might be right for
Primary Peritoneal CancerFallopian Tube CancerEpithelial Ovarian Cancer
RemeGen Co., Ltd. 43